Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer

In total, 70 patients were enrolled into this phase II study, to evaluate the activity of the pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) combination in recurrent ovarian cancer patients. PLD, 30 mg m(−2), was administered on day 1 by 60′ i.v. infusion, followed by GEM, 1000 mg m(−2)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: D'Agostino, G, Ferrandina, G, Ludovisi, M, Testa, A, Lorusso, D, Gbaguidi, N, Breda, E, Mancuso, S, Scambia, G
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2003
Aiheet:
Clinical
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2394291/
https://ncbi.nlm.nih.gov/pubmed/14520442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601284
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia